Page last updated: 2024-10-24

endocrine pancreas development

Definition

Target type: biologicalprocess

The process whose specific outcome is the progression of the endocrine pancreas over time, from its formation to the mature structure. The endocrine pancreas is made up of islet cells that produce insulin, glucagon and somatostatin. [GOC:cvs]

The endocrine pancreas, responsible for hormone production and blood glucose regulation, develops through a complex and precisely orchestrated series of events. This process begins with the formation of the pancreatic bud from the endoderm of the primitive gut tube. As the bud expands and differentiates, it gives rise to both exocrine and endocrine compartments. The endocrine pancreas arises from specialized cells, known as endocrine progenitors, that arise within the developing bud. These progenitors express specific transcription factors, such as Pdx1 and Ngn3, which are critical for their commitment to endocrine fate.

Once endocrine progenitors are established, they undergo further differentiation into the various endocrine cell types, including alpha cells (glucagon), beta cells (insulin), delta cells (somatostatin), and PP cells (pancreatic polypeptide). The differentiation process is influenced by a complex interplay of signaling molecules, transcription factors, and epigenetic modifications. Notably, Notch signaling plays a crucial role in regulating the balance between endocrine and exocrine cell fates, while Wnt signaling promotes endocrine differentiation.

Endocrine cell development involves the expression of specific hormone genes and the acquisition of functional secretory granules containing the respective hormones. These granules are crucial for storing and releasing hormones in response to physiological cues.

Furthermore, the developing endocrine pancreas undergoes a process of vascularization, providing a rich blood supply for hormone release and distribution throughout the body.

The proper development of the endocrine pancreas is essential for maintaining glucose homeostasis and overall metabolic health. Dysregulation of this process can lead to various endocrine disorders, such as diabetes mellitus. Understanding the intricate molecular mechanisms governing endocrine pancreas development is crucial for developing therapeutic strategies for these disorders.'
"

Proteins (4)

ProteinDefinitionTaxonomy
Eukaryotic translation initiation factor 2-alpha kinase 3A eukaryotic translation initiation factor 2-alpha kinase 3 that is encoded in the genome of human. [PRO:CNx, UniProtKB:Q9NZJ5]Homo sapiens (human)
Bcl-2 homologous antagonist/killerA Bcl-2 homologous antagonist/killer that is encoded in the genome of human. [PRO:WCB, UniProtKB:Q16611]Homo sapiens (human)
Gastric inhibitory polypeptide receptorA gastric inhibitory polypeptide receptor that is encoded in the genome of human. [PRO:DNx, UniProtKB:P48546]Homo sapiens (human)
Interleukin-6An interleukin-6 that is encoded in the genome of human. [PRO:JAN, UniProtKB:P05231]Homo sapiens (human)

Compounds (16)

CompoundDefinitionClassesRoles
raloxifene hydrochlorideraloxifene hydrochloride : A hydrochloride salt resulting from the reaction of equimolar amounts of raloxifene and hydrogen chloride.

Raloxifene Hydrochloride: A second generation selective estrogen receptor modulator (SERM) used to prevent osteoporosis in postmenopausal women. It has estrogen agonist effects on bone and cholesterol metabolism but behaves as a complete estrogen antagonist on mammary gland and uterine tissue.
hydrochloridebone density conservation agent;
estrogen antagonist;
estrogen receptor modulator
bergeninbergenin: RN refers to (2R-(2alpha,3beta,4alpha,4aalpha,10bbeta))-isomer; structuretrihydroxybenzoic acidmetabolite
alexidine dihydrchloride
6-n-tridecylsalicylic acid6-n-tridecylsalicylic acid: structure given in first sourcehydroxybenzoic acid
5,6-dehydrokawain5,6-dehydrokawain: from Alpinia speciosa rhizoma; RN given for cpd without isomeric designation; structure given in first source2-pyranones;
aromatic ether
abt-737aromatic amine;
aryl sulfide;
biphenyls;
C-nitro compound;
monochlorobenzenes;
N-arylpiperazine;
N-sulfonylcarboxamide;
secondary amino compound;
tertiary amino compound
anti-allergic agent;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
B-cell lymphoma 2 inhibitor
mk-0893
entrectinibentrectinib : A member of the class of indazoles that is 1H-indazole substituted by [4-(4-methylpiperazin-1-yl)-2-(tetrahydro-2H-pyran-4-ylamino)benzoyl]amino and 3,5-difluorobenzyl groups at positions 3 and 5, respectively. It is a potent inhibitor of TRKA, TRKB, TRKC, ROS1, and ALK (IC50 values of 0.1 to 1.7 nM), and used for the treatment of NTRK, ROS1 and ALK gene fusion-positive solid tumours.

entrectinib: inhibits TRK, ROS1, and ALK receptor tyrosine kinases; structure in first source
benzamides;
difluorobenzene;
indazoles;
N-methylpiperazine;
oxanes;
secondary amino compound;
secondary carboxamide
antibacterial agent;
antineoplastic agent;
apoptosis inducer;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor
meiogynin ameiogynin A: from the bark of Meiogyne cylindrocarpa; structure in first source
bi 653048 bs h3po4BI 653048 BS H3PO4: structure in first source
nms p937NMS P937: a polo-like kinase 1 inhibitor; structure in first source
nms-p118NMS-P118: a PARP-1 inhibitor; structure in first source
gsk2656157biaryl;
indoles;
methylpyridines;
organofluorine compound;
pyrrolopyrimidine;
tertiary carboxamide
antineoplastic agent;
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor;
PERK inhibitor
7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1h-indol-5-yl)-7h-pyrrolo(2,3-d)pyrimidin-4-amine7-methyl-5-(1-((3-(trifluoromethyl)phenyl)acetyl)-2,3-dihydro-1H-indol-5-yl)-7H-pyrrolo(2,3-d)pyrimidin-4-amine: inhibits protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK); structure in first source
jy-1-106JY-1-106: a BH3 alpha-helix mimetic that functions as a pan-Bcl-2 inhibitor; structure in first source
nms-e973NMS-E973: structure in first source